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Background: The purpose of this study was to evaluate the efﬁcacy and safety of Xylocaine spray for the
pain caused by endotracheal tube, and its impact on patients’ satisfaction of intensive care.
Methods: A quantitative evaluation of the effect before and after Xylocaine spray on endotracheal tube
pain relief, and a qualitative interview study of the impact of this intervention on patients’ satis-
faction of intensive care in a prospective, clinical investigation. Those in the medical intensive care
unit being endotracheal intubated and being able to clearly communicate with the caregivers were
enrolled after providing their inform consent. We prescribed Xylocaine 10% pump spray as frequently
as demanded.
Results: Nineteen patients were eligible for this study. The numerical rating scale of the throat pain before
local Xylocaine spray were 8.82 0.79, 7.98 0.92, 7.07 0.76, 6.37 0.83 and 5.47 1.23, sequentially,
compared with after therapy results, which were 3.84 0.86, 3.57 0.74, 3.06 0.70, 2.61 0.77 and
1.96 0.88 (p< 0.01). The interval between Xylocaine demanded gradually increased with time after
endotracheal tube intubation, and was also different between the daytime and the night-time on the ﬁrst
day of admission (p< 0.001). Most of the patients suffered from throat pain due to endotracheal intu-
bation, and they agreed their satisfaction was affected by the factors, the level of throat pain being
controlled (correlation: 0.89, p< 0.01), and the caregivers’ attitude with regard to the pain control
(correlation: 0.46, p< 0.05).
Conclusion: Xylocaine spray is demanded is an effective therapy to manage the pain caused by endo-
tracheal tube, which is also crucial to meet patient satisfaction in intensive care.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
One of the roles of palliative care in an intensive care unit (ICU)
is tominimize discomfort to improve the quality of medical care1e6.
Patients in ICU who are at risk of death also have a number of
considerably distressing symptoms7,8. The psychological anderest.
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iwan Society of Geriatric Emergenphysical adverse effects of such pain on patients is a concern4,9. A
life-sustaining procedure is one of the origins of this stress7,8. The
majority of patients in ICU experience considerable pain caused by
the endotracheal tube (ETT)7,8,10. With the therapeutic action of
blunting pain, the pulmonary, airway, cardiac, cognitive, and
infectious complications caused by endotracheal tube use can be
signiﬁcantly reduced4,9. However, to date there has been no article
discussing pain control caused by ETT.
Several types of management of pain elimination in the ICU
have been recommended, including lidocaine11e13. Lidocaine is
used as an analgesic and antiarrhythmic agent because it increases
the threshold of electrical excitability by inhibition of the perme-
ability of transient sodium inﬂux14. Although it can be used locallycy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Patient characteristics in the study.
Mean SD, or n(%) Minimum Maximum Range
Age 68.58 12.08 48 89 41
 65 10 (52.6)




APACHE score 21.89 2.11 17 25 8
BMI 21.08 5.50 16.8 29 12.2
Endo size 7.45 0.23 7 8 1
Endo day 6.68 4.36 2 18 16
ICU day 8.47 4.65 3 20 17






Organ failuresf 2 0 2 2
APACHE¼ acute physiology and chronic health evaluation; BMI¼ body mass index;
endo day¼ the duration of endotracheal intubation; endo size¼ the size of endo-
tracheal tube; ICU day¼ the duration of intensive care unit stay; Xylocaine
hour¼ the duration of Xylocaine.
a Pulmonary diseases included asthma, chronic obstructive pulmonary disease,
and pneumonia.
b Heart diseases included congestive heart failure.
c Digestive diseases included gastric ulcer bleeding and esophageal varices
bleeding.
d Renal diseases included chronic renal failure, uremia, and urinary tract infection.
e Infections included pneumonia and urinary tract infection.
f Organ failures included acute respiratory failure, acute renal failure, and
congestive heart failure.
Table 2
The inﬂuence factors related to the effects of the xylocaine spray on the pain control
caused by endotracheal tube.
Variable Estimate SEM T p value Posthoc testa
Sex
Female d d d d
Male 0.01 0.38 0.04 0.97
Age
 65 yr 0.45 0.32 1.42 0.21
<65 yr d d d d
APACHE score 0.13 0.08 1.60 0.16
BMI 0.00 0.03 0.07 0.95
Endo size 1.23 0.81 1.50 0.18
Endo day 0.09 0.23 0.40 0.70
ICU day 0.06 0.24 0.27 0.80
Time
Time-1 d d d d
Time-2 0.57 0.23 2.42 0.02 Time-1> Time-3
Time-3 0.97 0.23 4.15 p< 0.01 Time-1> Time-4
Time-4 1.22 0.23 5.20 p< 0.01 Time-1> Time-5
Time-5 1.47 0.23 6.26 p< 0.01 Time-2> Time-5
APACHE¼ acute physiology and chronic health evaluation; BMI¼ body mass index;
endo day¼ the duration of endotracheal intubation; endo size¼ the size of endo-
tracheal tube; ICU day¼ the duration of intensive care unit stay; SEM¼ standard
error of mean.
a Posthoc test: Adjustment by Bonferroni Multiple Comparisons.
S.-Y. Lee et al.12or systematically14, topical application to control ETT-induced
pain has never been evaluated. Since lower plasma lidocaine
concentrations can have the same effect as intravenous methods15,
the considerable side effects in systemic administration14 and due
to the beneﬁts of the administration route, we prescribed Xylocaine
pump spray 10% (50 ml/500 spray, AstraZeneca AB, Södertälje,
Sweden) on the oropharyngeal wall for the conscious patients who
were experiencing pain caused by ETT. This was done to evaluate
the efﬁcacy and safety of lidocaine, as well as to evaluate its impact
on patient satisfaction.
2. Participants and methods
This prospective clinical investigation was held at a 10-bed ICU
belonging to an academic, university-afﬁliated, tertiary-care, urban
medical center from April 1, 2009, throughMay 31, 2009. Except for
the patients with history of lidocaine-induced adverse effects or
lidocaine allergy, conscious patients suffering from pain caused by
the ETT without demand for other sedatives and analgesics were
eligible for this study after obtaining informed consent. The study
was approved by the Institutional Review Board (reference code
MMH-I-S-567).
2.1. Investigation
The treatment prescribed to patients enrolled involved Xylo-
caine 10% pump spray (50 ml/500 spray, AstraZeneca AB) with no
more than three puffs each time, and it could be used as frequently
as demanded. The severity of the pain was recorded using a self-
reporting numerical rating scale, each time before and 5 minutes
after the spray16. If any adverse effects of lidocaine usage were
noted, including conscious change, seizure14,17e19, mucous irrita-
tion, cyanosis14, and electrocardiography change, we would record
them, promptly discontinue drug delivery, and treat the patients
promptly. Before the patients left the ICU, they were asked to
complete the questionnaire.
2.2. Xylocaine 10% pump spray
Xylocaine 10% pump spray containing 10 mg lidocaine hydro-
chloride with each spray can be applied topically for local anes-
thesia. When it is sprayed on the oropharyngeal area, it has the
characteristics of rapid onset of action (3 to 5 minutes)14, short
duration (elimination half-life: 1.6 hours in healthy patients, 6.6
hours in patients with liver disease)20, dose-dependent serum
concentration21, and concentration-dependent toxicity22 (safe and
effective dose in the therapeutic concentration range, 2 to 4 mg/ml:
127e320 mg). Except for the local mucous irritation of lidocine23,
an overdose of lidocaine may also cause central nerve system
toxicity, such as seizure18,19,22.
2.3. Numerical rating scale
Being a good tool to evaluate pain in the ICU24, a self-reporting
numerical rating scale was chosen to evaluate the pain caused by
the ETT in the study. The self-reporting numerical rating scale used
ratings from 0e10, with 0 being painless and 10 being the most
painful, and it was accompaniedwith pictures of the face pain scale.
2.4. Questionnaire
To evaluate patient satisfaction of throat pain control, and of the
ICU care, a questionnaire with ﬁve Likert questionnaire items was
designed (Table 3). Each of the questionnaire items was scored to
quantify the results.2.5. Statistical analysis
A pretest investigation was held to determine the patient
numbers for evaluation. As the power was set at 0.8, and since the
datawas being analyzed by repeated analyses of variance (ANOVA),
10 patients were required.
Descriptive statistics for continuous variables were calculated
and were reported as mean standard deviation (SD). Categorical
variables were described using frequency distributions and were
Table 3
The inﬂuence of xylocaine spray for the ETT-induced throat pain on patient satis-
faction of intensive care.
Mean SD Minimum Maximum Range
(1) 0.47 0.90 0 75 75
(2) 88.16 15.29 50 100 50
(3) 94.74 10.47 75 100 25
(4) 86.84 21.03 25 100 75
(5) 88.16 15.29 50 100 50
(6) 88.16 17.42 50 100 50
Questionnairea 1 2 3 4 5 6
1 1.00
2 0.13 1.00
3 0.02 0.02 1.00
4 0.20 0.30 0.30 1.00
5 0.07 0.34 0.46y 0.89z 1.00
6 0.15 0.43 0.02 0.40 0.49y 1.00
a Questionnaire:
1. How many times have you been intubated with ETT? Never (0), once (25), twice
(50), three times (75), more than three times (100).
2. Did the ETT cause the throat pain this time? Agree strongly (100), agree slightly
(75), neutral (50), disagree slightly (25), disagree strongly (0).
3. Did you agree that the caregivers have treated your throat pain aggressively?
Agree strongly (100), agree (75), neutral (50), disagree slightly (25), disagree
strongly (0).
4. Were the medications sufﬁcient to control your throat pain caused by the ETT?
Agree strongly (100), agree (75), neutral (50), disagree slightly (25), disagree
strongly (0).
5. Did you satisfy to this ICU care? Agree strongly (100), agree (75), neutral (50),
disagree slightly (25), disagree strongly (0).
6 Would the level of the throat pain being controlled inﬂuence your satisfaction of
the ICU care? Agree strongly (100), agree (75), neutral (50), disagree slightly (25),
disagree strongly (0).
ETT¼ endotracheal tube.
Pearson’s correlation coefﬁcient, yp< 0.05, zp< 0.01.
Xylocaine for Pain Caused by Endotracheal Tube 13reported as n (%). A t test for independent samples was used to
detect two period differences in the means of continuous variables
(scores). The severity of pain before and after management over
times were analyzed by paired t test and repeated ANOVA
measures, followed by a Bonferroni posthoc test. For the applica-
bility of statistics, 2 participants who demanded Xylocaine less than
ﬁve sprays to control the pain caused by the endotracheal extu-
bation were excluded in the repeated ANOVA. The correlation
between satisfaction scores was determined using Pearson’sFig. 1. The patterns of the throat pain caused by the endcorrelation coefﬁcients. Owing to the confounders, the joint effects
of eight variables (time, sex, age, acute physiology and chronic
health evaluation, body mass index, the duration of the endotra-
cheal intubation, the size of the ETT, and the duration of the ICU
stay) on pre-post scores were investigated by general linear mixed
models (GLMM). Statistical analysis was performed using the
Statistical Package for the Social Science SPSS, version 15.0 and
Prism 3.0 (Chicago, USA). A two-tailed p value of 0.05 was consid-
ered a signiﬁcant level.
3. Results
The patient characteristics in the study are shown in Table 1. Ten
men and nine womenwere enrolled after providing their informed
consent. A total of 10 patients were more than 65 years old (52.6%).
The mean duration of Xylocaine demanded was 45 hours. No
adverse effects were complained of or observed in the study.
The numerical rating scale of the throat pain immediately before
local Xylocaine spray were 8.82 0.79, 7.98 0.92, 7.07 0.76,
6.37 0.83, and 5.471.23, and those of 5 minutes after local
Xylocaine spray were 3.84 0.86, 3.57 0.74, 3.06 0.70, 2.61
0.77, and 1.96 0.88. The severity of the throat pain caused by
ETT was reduced signiﬁcantly by local Xylocaine spray (p< 0.01,
Fig. 1). Two patients enrolled each required Xylocaine fore and
three times with the scale before spray each time: 8 and 8, 7 and 8,
6 and 6, 5, and the scale after spray each time: 3 and 3, 3 and 3.5, 2
and 3, 1. The pain severities before management declined gradually
with time (p< 0.01, Fig. 1). The pain reliving effect of Xylocaine was
not affected by sex, age, disease severity, body mass index, ETT size,
the duration of the endotracheal intubation, or the duration of the
ICU stay (Table 2), but the effect of pain relief declined related to
time (p< 0.01, Fig. 1 and Table 2). Expect for one patient that
needed the lidocaine for 121 hours, most of the patients stopped
requesting it within 48 hours. In addition, the interval between the
previous use of Xylocaine and following use gradually increased
from 4.311.68, 6.07 2.88, and 6.88 3.86 to 6.24 2.28 hours
(Fig. 2). The intervals of the demand of the pain relief were also
different between the daytime and the nighttime on the ﬁrst day of
admission (p< 0.001, Fig. 3).
Most of the patients experienced throat pain due to endotra-
cheal intubation for the ﬁrst time. Most patients agreed that theotracheal tube during local Xylocaine management.
Fig. 2. The interval between each time of the patients’ request of the local Xylocaine
pain control.
S.-Y. Lee et al.14caregivers had an aggressive attitude to manage their pain, and the
medications worked well. Most of themwere satisﬁed with the ICU
care, and they agreed that the level of the throat pain control would
inﬂuence their satisfaction with regard to ICU care (Table 3). The
level of the throat pain being controlled by the medications in the
ICU was correlated well with the degree of patient satisfaction of
the ICU care [correlation: 0.89 (p< 0.01), Table 3]. The caregivers’
attitude regarding pain control and the level of the throat pain
caused by the ETT being controlled are the part of the consideration
of their ICU satisfaction [correlation: 0.46 (p< 0.05) and 0.49
(p< 0.01) respectively]. The results are shown in Table 3.
4. Discussion
Endotracheal intubation is a general life-sustaining therapy;
however, it is also the most common and the most painful origin of
patient stress in the ICU7,8,10,25e27. In the literature review, the
severity of the throat pain was high, but varied in the intubated
patients in ICU7,10,25,28. The phenomenon depends not only on the
extent of the tissue injury, but also on patient idiosyncratic
appraisal, which is inﬂuenced by current mood, symptoms inter-
pretation, and response expectation25,28e30. The gate control
theory has supplied a ﬁrm physiologic basis for the phenomenon,
and it has subsequently been proved in many experiments31e33.
Patients in the ICU who are stressed by physiologic, psychological
and environmental stress, such as dyspnea, communication difﬁ-
culty, anxiety, and noise would aggravate their experience whenFig. 3. Daily variation of the interval between each time of the patients’ request of the
local Xylocaine pain control.intubated7,25,26. Because of the inability of verbal communication,
therefore, the throat pain caused by ETT is usually unexpectedly
and requires special care provided by the medical professionals25.
The discomfort has been seriously considered in the pediatric ﬁeld5.
In this study, the pain perception also showed the high variety
among the participants who have the initial severity scale ranged
from 8 to 10, the last scale before stopping request ranged from 4 to
6, and minimal request of three sprays, while one patient took 122
hours to treat the throat pain until the scale reached 1.
Clinically, pain in the ICU was controlled by opioids, nonste-
roidal anti-inﬂammatory drugs, and acetaminophen3,34. Lidocaine
is another type of analgesia that has been topically applied for
airway management to prevent discomfort induced by laryngeal
mask airway in rapid sequence intubation13,35, as well as to prevent
the airway effects of endotracheal intubation, such as cough, lar-
yngospasm36, and tachycardia15. This study further proved that
topical lidocaine spray was effective to relieve the pain caused by
the ETT without obvious side effects. In the view of the fact that the
ETT is one of the stressors in the ICU7,8,10, we suggested lidocaine
spray as an option for pain control caused by ETT.
Although the previous studies have shown lidocaine spray to
have the pharmacokinetics of rapid onset of action14, short dura-
tion in healthy20, dose-dependent serum concentration21, and
concentration-dependent toxicity22, how to apply it to control
pain for a period of time does not seem to have been established.
In addition, central gate control and neuroplasticity can modify
the pathologic pain31e33. In this study, the severity of throat
pain caused by ETT was positively correlated to the patients’
consciousness level, but it was inversely correlated to the time
sequence after the intubation or the number of lidocaine spray;
nevertheless, was not related to the age, sex, disease severity, body
weight, or the size of ETT. The results have shown prescription of
lidocaine spray on demand was the suitable way to treat throat
pain caused by the ETT.
The patients’ impression of the aggressiveness of the caregivers
attitude toward the pain was moderately correlated to their satis-
faction of the care, which could be the cause of the pain severity
decline with the time via the mechanism of central neuro-
plasticity32, a dynamic pain shaping according to the new signals,
including behavior and the stress. These results are quite compa-
rable with the gate control theory of pain, which proposed that the
transmission of nerve impulse from afferent ﬁbers to spinal cord is
modulated by gating mechanism in the spinal cord. The spinal
gating mechanism is inﬂuenced by the brain, the body-self neu-
romatrix that is composed of sensory, affective, and cognitive
neuromodules33. In view of the physiologic and psychological
effects of lidocaine spray on the pain control of ETT, which could
prevent the viscous cycle between the stress and the pain
severity33, and the unpredictable individual dynamic requirement
of a pain reliever, giving lidocaine on demand should be the best
method of clinical prescription.
Quality of care of patient and family satisfaction of the intensive
care unity survey of ICU care has been receiving attention from
specialists in critical care10,30,37e39. This study further demon-
strated that the care of patient throat pain induced by the ETT was
one point of consideration in their satisfaction of ICU care. In
addition, not only the effectiveness of ETT induced pain controlled
by the lidocaine, but also the perception of their caregivers’ attitude
and action toward the issue of pain control itself would signiﬁcantly
inﬂuence their satisfaction.
4.1. Study limitations
This studywas not placebo controlled because of the difﬁculty of
the manufacture preparation process approved by the company.
Xylocaine for Pain Caused by Endotracheal Tube 15However, the physical and psychological effects of lidocaine spray
on ETT-induced pain control has been proven in this pilot study,
which was a randomized, double blinded, large population study
that compared the effect on this issue between Xylocaine 10% spray
to traditional management is recommended.
5. Conclusion
Xylocaine spray administration on demand is an effectiveway to
control the pain caused by ETT. Applying this medication for the
stress commonly occurred in the ICU could also increase patient
satisfaction of the intensive care.
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